FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Pearce IP grows practice with senior patent hire

29 January 2026 Melbourne-based firm adds senior attorney with over 25 years of experience in therapeutics, diagnostics and biologics as demand for specialist patent services rises.

Americas

Sanofi suffers setback in insulin monopoly dispute

29 January 2026 A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.

Careers

Firm adds seven-lawyer team in second major merger

29 January 2026 New York-based firm makes its second key acquisition in weeks, as the firm pursues growth by broadening its litigation capabilities.